First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
Related Experiment Video
Updated: Oct 10, 2025
Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing
Published on: May 12, 2023
Sebastiano Buti1, Melissa Bersanelli1, Francesco Massari2
1Medical Oncology Unit, University Hospital of Parma, Parma 43126, Italy.
Background:
Non-clear cell (ncc) metastatic renal-cell carcinoma (RCC) has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart. New systemic combination therapies have emerged for metastatic RCC (mRCC), but the pivotal phase III trials excluded patients with nccRCC, which constitute about 30% of metastatic RCC cases.
Aim:
To provide a piece of real-life evidence on the use of pazopanib in this patient subgroup.
Methods:
The present study is a multicenter retrospective observational analysis aiming to assess the activity, efficacy, and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life setting.
Results:
Overall, 48 patients were included. At the median follow-up of 40.6 mo, the objective response rate was 27.1%, the disease control rate was 83.3%, and the median progression-free survival and overall survival were 12.3 (95% confidence interval [CI]: 3.6-20.9) and 27.7 (95%CI: 18.2-37.1) mo, respectively. Grade 3 adverse events occurred in 20% of patients, and no grade 4 or 5 toxicities were found.
Conclusion:
Pazopanib should be considered as a good first-line option for metastatic RCC with variant histology.
Insights
Pazopanib shows promising efficacy and manageable safety as a first-line treatment for advanced non-clear cell metastatic renal-cell carcinoma (RCC). This study offers real-world evidence for this patient subgroup often excluded from major trials.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Non-clear cell metastatic renal-cell carcinoma (ncc mRCC) has poor outcomes with standard therapies.
- Pivotal trials for metastatic RCC (mRCC) treatments excluded ncc mRCC patients, representing 30% of cases.
Purpose of the Study:
- To evaluate pazopanib's real-world activity, efficacy, and safety.
- To provide evidence for first-line therapy in advanced nccRCC patients.
Main Methods:
- Multicenter retrospective observational analysis.
- Assessed pazopanib as first-line treatment for advanced nccRCC.
- Included 48 patients.
Main Results:
- Objective response rate: 27.1%.
- Disease control rate: 83.3%.
- Median progression-free survival: 12.3 months.
- Median overall survival: 27.7 months.
- Grade 3 adverse events in 20% of patients; no grade 4/5 toxicity.
Conclusions:
- Pazopanib is a viable first-line option for metastatic RCC with non-clear cell histology.
- Real-world data supports pazopanib's use in this underrepresented patient group.
More Related Videos
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
09:02Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Related Concept Videos
02:56Treatment Resistant Cancers
01:06Renal Drug Clearance: Overview
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...